Goldman Sachs has resumed coverage of DBV Technologies (DBVT, Financial), assigning it a Sell rating with a price target of $7.25, suggesting a potential 14% decline. Although the company has recently advanced its regulatory journey for Viaskin Peanut, providing greater clarity and confidence, the analyst notes that DBV's plan to independently market the product is fraught with risks. The key milestone in 2025, the Phase 3 VITESSE trial results, is anticipated to be favorable. However, any share price increase might be constrained by warrant exercises leading to substantial dilution. Consequently, there appears to be little motivation for new investors to engage with the stock prior to these results.
DBVT Faces Challenges Despite Regulatory Progress | DBVT Stock News
May 29, 2025
Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers